A new mouse model may be critical for understanding the most aggressive types of pancreatic cancer and finding ways to prevent its growth and recurrence.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
Columbia cancer researchers estimate that 60% of patients in a phase 2 clinical trial will have no sign of their cancer two years after treatment with combination therapy.
Heavy ions could radically improve radiation therapy for cancer treatment, but research is needed to understand how they work. With the aid of a new instrument at Columbia, scientists aim to find out.
Columbia's Lisa A. Kachnic, MD, a pioneer in radiation oncology, discusses the advancements made in the field of radiotherapy and the innovation to come.
In the future, bacteria may be let loose in the body to seek and destroy cancer cells, but the bacteria need a way to hide from our immune system. Columbia biomedical engineers may have a solution.
Having a rapport with kids is a critical part of the job for James Church and other Columbia colorectal surgeons who treat people with hereditary colon cancer.
Lung cancer often spreads to the brain. Columbia scientists have now uncovered a tactic used by metastases to hide in the brain and identified a drug combination that can potentially target them.
By applying artificial intelligence to standard-of-care imaging, Columbia cancer researchers can predict how well immunotherapy will work for patients with melanoma.